HBV-话题@MedSci

#HBV#

159篇内容 | 4640人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2172684, encodeId=956a21e268443, content=<a href='/topic/show?id=1a942339426' target=_blank style='color:#2F92EE;'>#乙型肝炎#</a> <a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a> <a href='/topic/show?id=2be61e0740' target=_blank style='color:#2F92EE;'>#AAV载体#</a> <a href='/topic/show?id=082010820436' target=_blank style='color:#2F92EE;'>#分泌信号肽#</a>, objectTitle=Gut：复旦大学王勇翔/袁正宏发现抑制乙肝表面抗原分泌的新策略, objectType=article, longId=801279, objectId=86498012e920, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230326/1679867598346_4754896.jpeg, objectUrl=/article/show_article.do?id=86498012e920, replyNumber=0, likeNumber=97, createdTime=2023-12-03, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=86498012e920, moduleTitle=Gut：复旦大学王勇翔/袁正宏发现抑制乙肝表面抗原分泌的新策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86498012e920)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2156557, encodeId=af57215655ed0, content=<a href='/topic/show?id=7826104e2900' target=_blank style='color:#2F92EE;'>#bepirovirsen#</a>可实现<a href='/topic/show?id=9bfe106598cf' target=_blank style='color:#2F92EE;'>#HBV感染者#</a>长期<a href='/topic/show?id=b5a4328934f' target=_blank style='color:#2F92EE;'>#功能性治愈#</a><a href='/topic/show?id=cf292341925' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=cf292341925' target=_blank style='color:#2F92EE;'>#乙肝#</a></a>，不过目前也仅9-10%的<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>感染者在接受24周治疗后实现。如果长时间，会不会有更高比例的治愈率？？确实<a href='/topic/show?id=cf292341925' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=cf292341925' target=_blank style='color:#2F92EE;'>#乙肝#</a></a>与<a href='/topic/show?id=d14f2092446' target=_blank style='color:#2F92EE;'>#丙肝#</a>相比，难搞多了!, objectTitle=NEJM：Bepirovirsen可实现HBV感染者长期功能性治愈, objectType=article, longId=751011, objectId=6c25e5101102, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221207/1670400514594_2051781.png, objectUrl=/article/show_article.do?id=6c25e5101102, replyNumber=0, likeNumber=102, createdTime=2023-09-07, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=6c25e5101102, moduleTitle=NEJM：Bepirovirsen可实现HBV感染者长期功能性治愈, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c25e5101102)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1836716, encodeId=22011836e166c, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, objectTitle=Front Immunol：中国南方河源市隐匿性乙型肝炎病毒感染献血者中发现的高频显著HBV突变, objectType=article, longId=730669, objectId=2efce3066996, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2efce3066996, replyNumber=0, likeNumber=97, createdTime=2022-08-15, rootId=0, userName=klivis, userId=e87531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2efce3066996, moduleTitle=Front Immunol：中国南方河源市隐匿性乙型肝炎病毒感染献血者中发现的高频显著HBV突变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2efce3066996)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2116819, encodeId=c9012116819ad, content=这个研究对中国有现实意义，因为中国合并<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>的人很多。合并的<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>再激活率为2.0%，这个比例也不小了，值得重视。不过分析发现，<a href='/topic/show?id=820e3228e1b' target=_blank style='color:#2F92EE;'>#利妥昔单抗#</a>(RTX)、<a href='/topic/show?id=60ba9e805ae' target=_blank style='color:#2F92EE;'>#阿巴西普#</a>以及<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a>、白介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)抑制剂的<a href='/topic/show?id=fdd01053199b' target=_blank style='color:#2F92EE;'>#HBV再激活率#</a>为9.0%，6.0% ，1.0%，0.0%，0.0%。总体而言，JAK抑制剂是安全的，当然<a href='/topic/show?id=e0d7546812c' target=_blank style='color:#2F92EE;'>#托珠单抗#</a>等更安全, objectTitle=Immun Inflamm Dis：生物制剂或JAK抑制剂治疗类风湿性关节炎后HBsAg -/ HBcAb+患者乙型肝炎再激活的风险, objectType=article, longId=761107, objectId=9106e611071d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668024114319_4754896.jpeg, objectUrl=/article/show_article.do?id=9106e611071d, replyNumber=0, likeNumber=156, createdTime=2023-02-28, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=9106e611071d, moduleTitle=Immun Inflamm Dis：生物制剂或JAK抑制剂治疗类风湿性关节炎后HBsAg -/ HBcAb+患者乙型肝炎再激活的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9106e611071d)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1836715, encodeId=14281836e1527, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, objectTitle=Front Immunol：HBV感染肝癌患者接受PD-1抑制剂联合治疗时HBV DNA和乙肝表面抗原水平与肿瘤疗效、肝功能和免疫学指标的相关性, objectType=article, longId=730662, objectId=e010e3066291, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e010e3066291, replyNumber=0, likeNumber=121, createdTime=2023-01-25, rootId=0, userName=klivis, userId=e87531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e010e3066291, moduleTitle=Front Immunol：HBV感染肝癌患者接受PD-1抑制剂联合治疗时HBV DNA和乙肝表面抗原水平与肿瘤疗效、肝功能和免疫学指标的相关性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e010e3066291)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1836709, encodeId=77c21836e099c, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, objectTitle=ARD：乙型肝炎感染缓解患者的平均糖皮质激素剂量及HBV再激活和肝炎发作的风险, objectType=article, longId=293698, objectId=5b3f29369804, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b3f29369804, replyNumber=0, likeNumber=99, createdTime=2022-09-01, rootId=0, userName=klivis, userId=e87531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b3f29369804, moduleTitle=ARD：乙型肝炎感染缓解患者的平均糖皮质激素剂量及HBV再激活和肝炎发作的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b3f29369804)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1836718, encodeId=95db1836e181e, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, objectTitle=最新研究进展 | HBV RNA的临床价值与应用展望, objectType=article, longId=733815, objectId=391ce33815a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=391ce33815a1, replyNumber=0, likeNumber=85, createdTime=2022-12-01, rootId=0, userName=klivis, userId=e87531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=391ce33815a1, moduleTitle=最新研究进展 | HBV RNA的临床价值与应用展望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=391ce33815a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1836713, encodeId=0d4d1836e13f7, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, objectTitle=Front Oncol：AFP早期应答与仑伐替尼治疗HBV相关肝细胞癌生存相关, objectType=article, longId=299322, objectId=7c1e299322c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c1e299322c1, replyNumber=0, likeNumber=85, createdTime=2022-07-31, rootId=0, userName=klivis, userId=e87531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c1e299322c1, moduleTitle=Front Oncol：AFP早期应答与仑伐替尼治疗HBV相关肝细胞癌生存相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c1e299322c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1836708, encodeId=42521836e08c4, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, objectTitle=Int J Cancer：慢性乙型肝炎病毒(HBV)感染可增加某些胃肠道(GI)肿瘤的发病风险, objectType=article, longId=292069, objectId=157e29206907, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=157e29206907, replyNumber=0, likeNumber=97, createdTime=2022-05-13, rootId=0, userName=klivis, userId=e87531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=157e29206907, moduleTitle=Int J Cancer：慢性乙型肝炎病毒(HBV)感染可增加某些胃肠道(GI)肿瘤的发病风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=157e29206907)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1836717, encodeId=f69b1836e17a0, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, objectTitle=BMC Gastroenterology: 血浆超氧化物歧化酶水平在HBV相关慢加急性肝衰竭中的预后价值分析, objectType=article, longId=732072, objectId=1f9de320725b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f9de320725b, replyNumber=0, likeNumber=81, createdTime=2022-09-15, rootId=0, userName=klivis, userId=e87531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f9de320725b, moduleTitle=BMC Gastroenterology: 血浆超氧化物歧化酶水平在HBV相关慢加急性肝衰竭中的预后价值分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f9de320725b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1836712, encodeId=1a101836e1234, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, objectTitle=2022 APASL指南：妊娠期HBV感染, objectType=article, longId=295390, objectId=6aef29539049, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6aef29539049, replyNumber=0, likeNumber=67, createdTime=2022-07-02, rootId=0, userName=klivis, userId=e87531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6aef29539049, moduleTitle=2022 APASL指南：妊娠期HBV感染, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6aef29539049)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1836710, encodeId=45041836e1026, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, objectTitle=《2021年亚太肝病学会临床实践指南:与免疫抑制治疗相关的HBV再激活》摘译, objectType=article, longId=295205, objectId=5de729520580, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5de729520580, replyNumber=0, likeNumber=60, createdTime=2022-12-18, rootId=0, userName=klivis, userId=e87531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5de729520580, moduleTitle=《2021年亚太肝病学会临床实践指南:与免疫抑制治疗相关的HBV再激活》摘译, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5de729520580)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1836711, encodeId=85341836e11c8, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, objectTitle=JCO：H1-抗组胺药可降低HBV、HCV或HBV-HCV合并感染患者患肝细胞癌的风险, objectType=article, longId=295266, objectId=a52729526605, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a52729526605, replyNumber=0, likeNumber=87, createdTime=2022-02-16, rootId=0, userName=klivis, userId=e87531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a52729526605, moduleTitle=JCO：H1-抗组胺药可降低HBV、HCV或HBV-HCV合并感染患者患肝细胞癌的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a52729526605)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1836714, encodeId=aa831836e14d5, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, objectTitle=Front Immunol：HBeAg阳性慢性HBV感染孕妇产后肝炎暴发的临床特征及T细胞免疫特征, objectType=article, longId=727863, objectId=413de278637e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=413de278637e, replyNumber=0, likeNumber=83, createdTime=2022-06-07, rootId=0, userName=klivis, userId=e87531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=413de278637e, moduleTitle=Front Immunol：HBeAg阳性慢性HBV感染孕妇产后肝炎暴发的临床特征及T细胞免疫特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=413de278637e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1836704, encodeId=f3261836e04a2, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, objectTitle=Clin Immunol：HBV通过NF-Kb途径参与肝病的进展, objectType=article, longId=214160, objectId=98bb2141601d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98bb2141601d, replyNumber=0, likeNumber=86, createdTime=2021-07-29, rootId=0, userName=klivis, userId=e87531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98bb2141601d, moduleTitle=Clin Immunol：HBV通过NF-Kb途径参与肝病的进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=98bb2141601d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1836707, encodeId=93d91836e071e, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, objectTitle=更新！看更新版《中国肝细胞癌经动脉化疗栓塞治疗临床实践指南》谈接受介入治疗的HCC患者抗HBV治疗, objectType=article, longId=219167, objectId=456221916eb9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=456221916eb9, replyNumber=0, likeNumber=77, createdTime=2022-09-13, rootId=0, userName=klivis, userId=e87531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=456221916eb9, moduleTitle=更新！看更新版《中国肝细胞癌经动脉化疗栓塞治疗临床实践指南》谈接受介入治疗的HCC患者抗HBV治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=456221916eb9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1836706, encodeId=1a9b1836e0653, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, objectTitle=HEPATOLOGY：HBV 感染不会增加 COVID-19 患者的死亡率, objectType=article, longId=217903, objectId=f12821e903f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f12821e903f8, replyNumber=0, likeNumber=115, createdTime=2021-10-04, rootId=0, userName=klivis, userId=e87531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f12821e903f8, moduleTitle=HEPATOLOGY：HBV 感染不会增加 COVID-19 患者的死亡率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f12821e903f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1836705, encodeId=8c511836e0511, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, objectTitle=J Gastroenterology: CCL19可以增强CD8+T细胞反应并加速 HBV 清除, objectType=article, longId=214269, objectId=0d2321426943, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d2321426943, replyNumber=0, likeNumber=119, createdTime=2022-03-20, rootId=0, userName=klivis, userId=e87531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d2321426943, moduleTitle=J Gastroenterology: CCL19可以增强CD8+T细胞反应并加速 HBV 清除, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d2321426943)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1836700, encodeId=4d0a1836e00cf, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, objectTitle=Gastroenterology：核酸聚合物REP 2139/REP2165、替诺福韦联合干扰素可提高HBV治疗效果, objectType=article, longId=196774, objectId=af68196e7496, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af68196e7496, replyNumber=0, likeNumber=70, createdTime=2020-07-18, rootId=0, userName=klivis, userId=e87531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af68196e7496, moduleTitle=Gastroenterology：核酸聚合物REP 2139/REP2165、替诺福韦联合干扰素可提高HBV治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af68196e7496)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1836703, encodeId=b2f81836e03ee, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, objectTitle=J Gastroenterol：慢性乙肝患者体内残留的HBV DNA和pgRNA可使肝癌风险增加2-5倍！, objectType=article, longId=209221, objectId=7cda209221d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7cda209221d4, replyNumber=0, likeNumber=101, createdTime=2022-02-11, rootId=0, userName=klivis, userId=e87531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7cda209221d4, moduleTitle=J Gastroenterol：慢性乙肝患者体内残留的HBV DNA和pgRNA可使肝癌风险增加2-5倍！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7cda209221d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HBV

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#乙型肝炎# #HBV# #AAV载体# #分泌信号肽#

Gut：复旦大学王勇翔/袁正宏发现抑制乙肝表面抗原分泌的新策略

2023-12-03发表于上海

侠胆医心 (审核中...)

前往app查看评论内容

#bepirovirsen#可实现#HBV感染者#长期#功能性治愈##乙肝#，不过目前也仅9-10%的#HBV#感染者在接受24周治疗后实现。如果长时间，会不会有更高比例的治愈率？？确实 #乙肝#与#丙肝#相比，难搞多了!

NEJM：Bepirovirsen可实现HBV感染者长期功能性治愈

2023-09-07发表于上海

klivis (审核中...)

前往app查看评论内容

#HBV#

Front Immunol：中国南方河源市隐匿性乙型肝炎病毒感染献血者中发现的高频显著HBV突变

2022-08-15

showtest (审核中...)

前往app查看评论内容

全文收起这个研究对中国有现实意义，因为中国合并#慢性乙型肝炎#的人很多。合并的#HBV#再激活率为2.0%，这个比例也不小了，值得重视。不过分析发现，#利妥昔单抗#(RTX)、#阿巴西普#以及#JAK抑制剂#、白介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)抑制剂的#HBV再激活率#为9.0%，6.0% ，1.0%，0.0%，0.0%。总体而言，JAK抑制剂是安全的，当然#托珠单抗#等更安全

Immun Inflamm Dis：生物制剂或JAK抑制剂治疗类风湿性关节炎后HBsAg -/ HBcAb+患者乙型肝炎再激活的风险

2023-02-28发表于上海

klivis (审核中...)

前往app查看评论内容

#HBV#

Front Immunol：HBV感染肝癌患者接受PD-1抑制剂联合治疗时HBV DNA和乙肝表面抗原水平与肿瘤疗效、肝功能和免疫学指标的相关性

2023-01-25

klivis (审核中...)

前往app查看评论内容

#HBV#

ARD：乙型肝炎感染缓解患者的平均糖皮质激素剂量及HBV再激活和肝炎发作的风险

2022-09-01

klivis (审核中...)

前往app查看评论内容

#HBV#

最新研究进展 | HBV RNA的临床价值与应用展望

2022-12-01

klivis (审核中...)

前往app查看评论内容

#HBV#

Front Oncol：AFP早期应答与仑伐替尼治疗HBV相关肝细胞癌生存相关

2022-07-31

klivis (审核中...)

前往app查看评论内容

#HBV#

Int J Cancer：慢性乙型肝炎病毒(HBV)感染可增加某些胃肠道(GI)肿瘤的发病风险

2022-05-13

klivis (审核中...)

前往app查看评论内容

#HBV#

BMC Gastroenterology: 血浆超氧化物歧化酶水平在HBV相关慢加急性肝衰竭中的预后价值分析

2022-09-15

klivis (审核中...)

前往app查看评论内容

#HBV#

2022 APASL指南：妊娠期HBV感染

2022-07-02

klivis (审核中...)

前往app查看评论内容

#HBV#

《2021年亚太肝病学会临床实践指南:与免疫抑制治疗相关的HBV再激活》摘译

2022-12-18

klivis (审核中...)

前往app查看评论内容

#HBV#

JCO：H1-抗组胺药可降低HBV、HCV或HBV-HCV合并感染患者患肝细胞癌的风险

2022-02-16

klivis (审核中...)

前往app查看评论内容

#HBV#

Front Immunol：HBeAg阳性慢性HBV感染孕妇产后肝炎暴发的临床特征及T细胞免疫特征

2022-06-07

klivis (审核中...)

前往app查看评论内容

#HBV#

Clin Immunol：HBV通过NF-Kb途径参与肝病的进展

2021-07-29

klivis (审核中...)

前往app查看评论内容

#HBV#

更新！看更新版《中国肝细胞癌经动脉化疗栓塞治疗临床实践指南》谈接受介入治疗的HCC患者抗HBV治疗

2022-09-13

klivis (审核中...)

前往app查看评论内容

#HBV#

HEPATOLOGY：HBV 感染不会增加 COVID-19 患者的死亡率

2021-10-04

klivis (审核中...)

前往app查看评论内容

#HBV#

J Gastroenterology: CCL19可以增强CD8+T细胞反应并加速 HBV 清除

2022-03-20

klivis (审核中...)

前往app查看评论内容

#HBV#

Gastroenterology：核酸聚合物REP 2139/REP2165、替诺福韦联合干扰素可提高HBV治疗效果

2020-07-18

klivis (审核中...)

前往app查看评论内容

#HBV#

J Gastroenterol：慢性乙肝患者体内残留的HBV DNA和pgRNA可使肝癌风险增加2-5倍！

2022-02-11

科室
- - 订阅+
  - 更多科室
工具
服务